Q: Should beta-blockers be discontinued when a patient is admitted to the hospital with acutely decompensated heart failure?

A: Data on this topic are scant. However, most experts recommend discontinuing beta-blockers in patients with shock and lowering the dose for those with bradycardia or hypotension. All others should continue to receive a beta-blocker at the same dose they had been receiving.

Furthermore, the evidence clearly supports resuming (or starting) a beta-blocker after the patient attains a euvolemic state before he or she leaves the hospital unless a clear contraindication exists.

BETA-BLOCKERS: THE STANDARD FOR CHRONIC HEART FAILURE

Beta-adrenergic antagonists—specifically, metoprolol succinate (extended release) and carvedilol, the only agents of this class approved for this indication—are the standard of care for chronic heart failure because they have been proven to decrease mortality rates. They should also be beneficial in acutely decompensated heart failure because they help break the neurohormonal vicious circle that occurs in both conditions.

Crude mortality rates of patients after a first hospitalization for acutely decompensated heart failure are 11.6% at 30 days and 33% at 1 year. Brief periods of treatment with medication during the initial presentation of acutely decompensated heart failure may significantly affect long-term survival.

However, there are very few data on the efficacy and safety of continuing beta-blockers in patients admitted to the hospital with acutely decompensated heart failure.

The question has not been directly tested: an appropriate clinical trial would be difficult to design, and it would be difficult to recruit patients in acute decompensation to such a study. Consequently, the balance of risks (negative inotropic effects) and benefits (inhibiting the adverse effects of the sympathetic nervous system) of beta-blocker therapy has not been established in acute decompensation.

The uncertainty has led to inconsistent management: some physicians discontinue these drugs until the patient is close to euvoletic status, some reduce dosage, and others continue the patient’s outpatient regimen.

Patients with more severe symptoms of heart failure have more side effects at the
Start of beta-blocker therapy than those with milder disease. But one cannot assume that patients sick enough to be admitted to the hospital will not tolerate beta-blocker therapy: the hemodynamics of acutely decompensated heart failure differ from those of chronic severe heart failure. In fact, patients with severe symptoms (New York Heart Association [NYHA] class IV) on beta-blockers have a significantly lower mortality rate than comparable patients not taking beta-blockers. In addition, abruptly withdrawing beta-blockers in patients with heart failure results in clinical deterioration and should be avoided.

**RECOMMENDATIONS**

**FIGURE 2** is an algorithm to help guide decisions regarding beta-blockers for patients with acutely decompensated heart failure, based on vital signs and perfusion status. It assumes that the patient has been on a stable dose of a beta-blocker for at least a few weeks before being hospitalized. Again, we emphasize that a patient who is not already taking a beta-blocker should be started on one once he or she is in a compensated, euvolemic state, before leaving the hospital.

A comparable and practical approach for the overall pharmacologic management of patients with acutely decompensated heart failure is based on the patient’s congestion and perfusion status (**TABLE 1**).

In patients with adequate perfusion, every effort should be made to avoid reducing or stopping beta-blockers. Evidence indicates that beta-blockers can be continued in patients with worsening heart failure without compromising safety.

**Patients with shock, bradycardia, or hypotension.** Most experts recommend discontinuing beta-blockers in patients with shock and reducing the dosage for those who have bradycardia or hypotension. Treatment with diuretics should be optimized, and inotropes should be considered. Hemodynamic monitoring is recommended.

In patients with recurrent decompensation, briefly holding beta-blockers or significantly lowering the dose may be warranted (unless inappropriate therapy is to blame).

**Inotropic agents.** The routine use of inotropic agents is not recommended. However, for patients receiving a beta-blocker who need an inotropic agent because of low cardiac output, hypotension, or cardiogenic shock, a phosphodiesterase inhibitor such as milrinone is preferable to a beta-adrenergic agonist such as dobutamine or dopamine because phosphodiesterase inhibitors work at a site distal to beta-adrenergic receptors.
TABLE 1

Managing medications on the basis of congestion and perfusion status

<table>
<thead>
<tr>
<th>PERFUSION AND VOLUME STATUS</th>
<th>BETA-BLOCKER DOSE</th>
<th>DIURETIC DOSE</th>
<th>INOTROPIC MEDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;Wet and warm&quot; (congested, well perfused)</td>
<td>Don’t change</td>
<td>Increase</td>
<td>Usually not required</td>
</tr>
<tr>
<td>&quot;Wet and cold&quot; (congested, poorly perfused)</td>
<td>Hold or significantly reduce dose</td>
<td>Increase or don’t change</td>
<td>Usually required</td>
</tr>
<tr>
<td>&quot;Dry and warm&quot; (euvolemic or hypovolemic, well perfused)</td>
<td>Don’t change</td>
<td>Don’t change</td>
<td>Usually not required</td>
</tr>
<tr>
<td>&quot;Dry and cold&quot; (euvolemic or hypovolemic, poorly perfused)</td>
<td>Hold or significantly reduce dose</td>
<td>Hold or significantly reduce dose</td>
<td>Usually required</td>
</tr>
</tbody>
</table>

REFERENCES


ADDRESS: Wissam H. Fares, MD, Department of General Internal Medicine, 570, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail faresw@ccf.org.